• Rucaparib (AG-014699): PARP1 Inhibition and Mitochondrial...

  2026-02-18

  Discover how Rucaparib (AG-014699, PF-01367338), a potent PARP1 inhibitor, advances DNA damage response research by linking nuclear repair disruption to mitochondrial apoptosis. This article uniquely explores the intersection of PARP inhibition, RNA Pol II signaling, and radiosensitization in PTEN-deficient and ETS fusion-expressing cancer models.

• 3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for M...

  2026-02-18

  3-Aminobenzamide (PARP-IN-1) is a nanomolar-potency poly (ADP-ribose) polymerase inhibitor validated for use in CHO cells and disease models. This compound enables reproducible inhibition of PARP-mediated processes, supporting research into oxidative stress, endothelial function, and diabetic nephropathy.

• Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabo...

  2026-02-17

  Acifran, a high-purity HM74A/GPR109A and GPR109B agonist, is a precise tool for dissecting lipid metabolism regulation and advancing metabolic disorder research. Cryo-EM studies elucidate its atomic-level selectivity and mechanism, establishing Acifran as a gold standard for lipid signaling pathway modulation.

• PF-04971729 (Ertugliflozin): Mechanistic Precision and St...

  2026-02-17

  This thought-leadership article explores the mechanistic underpinnings and translational potential of PF-04971729 (Ertugliflozin) as a highly selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor. It blends rigorous scientific insight with actionable guidance, providing researchers with a framework to advance diabetes mellitus research and metabolic disease innovation. Key findings from peer-reviewed studies are contextualized, and strategic considerations for experimental design, clinical relevance, and future research trajectories are discussed. The piece distinguishes itself from typical product-focused content by integrating cross-disciplinary perspectives and forward-looking recommendations, while referencing APExBIO’s PF-04971729 as a cornerstone compound for advanced renal glucose transport and diabesity studies.

• Benzyl Quinolone Carboxylic Acid: Precision M1 Receptor P...

  2026-02-16

  Benzyl Quinolone Carboxylic Acid (BQCA) is a gold-standard positive allosteric modulator for M1 muscarinic acetylcholine receptors, enabling highly selective, reproducible, and quantitative enhancement of cognitive signaling. Leverage BQCA’s unique pharmacological profile for robust Alzheimer’s disease research, optimized neuronal assays, and advanced troubleshooting solutions.

• PF-04971729 (Ertugliflozin): Selective SGLT2 Inhibitor fo...

  2026-02-16

  PF-04971729 (Ertugliflozin) is a potent and highly selective oral SGLT2 inhibitor used for diabetes mellitus research. Its distinct pharmacokinetic profile and transporter selectivity enable reproducible assays in renal glucose transport studies. This article enumerates published benchmarks, application boundaries, and workflow integration parameters for PF-04971729.

• 3-Aminobenzamide (PARP-IN-1): Advanced Insights into PARP...

  2026-02-15

  Explore the multifaceted role of 3-Aminobenzamide (PARP-IN-1), a potent PARP inhibitor, in poly (ADP-ribose) polymerase inhibition, oxidative stress, and diabetic nephropathy research. This article delivers a unique, in-depth analysis of mechanism, emerging viral applications, and assay optimization strategies.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Precisio...

  2026-02-14

  The JC-1 Mitochondrial Membrane Potential Assay Kit empowers researchers with robust, ratiometric detection of mitochondrial membrane potential—crucial for apoptosis and mitochondrial function analysis. Its built-in controls, compatibility, and reliability make it indispensable for cancer research, neurodegenerative disease models, and drug screening. Discover hands-on workflows, advanced applications, and troubleshooting strategies for high-impact experimental success.

• DiscoveryProbe™ FDA-approved Drug Library: Transforming S...

  2026-02-13

  Explore how the DiscoveryProbe FDA-approved Drug Library advances signal pathway regulation, enabling next-generation drug repositioning screening and pharmacological target identification. This comprehensive analysis provides unique mechanistic insights and strategic applications beyond traditional high-throughput screening.

• LGK-974: Advanced Insights into PORCN Inhibition for Wnt-...

  2026-02-13

  Explore the unique molecular and translational landscape of LGK-974, a potent and specific PORCN inhibitor. Discover advanced mechanistic insights and future directions for Wnt-driven cancer therapy, including β-catenin signaling inhibition and applications in pancreatic and head and neck cancers.

• DiscoveryProbe FDA-approved Drug Library: Transforming Hi...

  2026-02-12

  The DiscoveryProbe™ FDA-approved Drug Library redefines high-throughput screening and drug repositioning with its rigorously curated, regulatory-approved bioactive compounds. Designed for seamless integration and robust data generation, this library empowers researchers to accelerate target identification, pharmacological profiling, and therapeutic discovery across oncology, neurodegeneration, and beyond.

• Rucaparib (AG-014699): Potent PARP1 Inhibitor for Radiose...

  2026-02-12

  Rucaparib (AG-014699, PF-01367338) is a powerful PARP1 inhibitor that transforms DNA damage response research and cancer biology workflows, especially in PTEN-deficient and ETS fusion-expressing models. This guide details hands-on protocols, experimental advantages, and troubleshooting strategies to maximize the radiosensitization potential of Rucaparib, as supplied by APExBIO.

• Benzyl Quinolone Carboxylic Acid: Selective M1 Muscarinic...

  2026-02-11

  Benzyl Quinolone Carboxylic Acid (BQCA) is a highly selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor, enabling precise modulation of cognitive function pathways. Rigorous studies confirm its >100-fold subtype selectivity, dose-dependent potentiation of acetylcholine, and robust brain penetration, making BQCA (C3869) a benchmark tool for Alzheimer's disease research and neuronal signaling studies.

• Benzyl Quinolone Carboxylic Acid: Mechanistic Insights in...

  2026-02-11

  Explore the advanced mechanisms by which Benzyl Quinolone Carboxylic Acid (BQCA) acts as a positive allosteric modulator of the M1 muscarinic acetylcholine receptor. This article uniquely integrates recent GRK-mediated signaling discoveries, offering fresh perspectives for cognitive function modulation and Alzheimer's disease research.

• DiscoveryProbe™ FDA-approved Drug Library: Mechanisms, Ev...

  2026-02-10

  The DiscoveryProbe™ FDA-approved Drug Library offers a rigorously curated collection of 2,320 bioactive compounds for high-throughput screening. As an APExBIO resource, it enables drug repositioning and precise pharmacological target identification across disease models. This article details the biological rationale, mechanisms, evidence, and workflow integration for this FDA-approved bioactive compound library.

15677 records 1/1046 page Next 12345 下5页 Last page